Genscript Biotech (STU:G51) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:G51 Genscript Biotech Corp STU:G51
67 GF Score
Price €1.42
GF Value €2.25
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genscript Biotech FFO?

FFO (Funds from operations) only applies to REITs.

STU:G51
67GF Score
Genscript Biotech Corp STU:G51
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Genscript Biotech (STU:G51) Overvalued in 2026?

Based on GuruFocus' analysis, Genscript Biotech stock appears to be undervalued. The current stock price of €1.42 is trading 36.9% below its estimated GF Value™ of €2.25. GuruFocus considers Genscript Biotech to be Significantly Undervalued.

Key valuation signals for STU:G51:

  • FFO:
  • GF Value™: €2.25 vs. price of €1.42 (36.9% below fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the STU:G51 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genscript Biotech Business Description

Other Exchanges GNNSF:USA01548:Hong Kong
Address 860 Centennial Avenue, Piscataway, NJ, USA, 08854
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
67GF Score

Get the complete analysis for STU:G51

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.42
Price
€2.25
GF Value